

Integra LifeSciences Announces Results of Stockholders' Vote at Annual Meeting

PLAINSBORO, N.J., May 17, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced at the annual meeting of stockholders today that David C. Auth, Ph.D., Keith Bradley, Ph.D., Richard E. Caruso, Ph.D., Stuart M. Essig, Neal Moszkowski, and James M. Sullivan were elected to the Company's Board of Directors for one-year terms. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent auditors and approved an amendment to the Company's Employee Stock Purchase Plan that increased the number of shares available for issuance under the Plan from 500,000 to 1,500,000.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,100 employees. Please visit our website at (http://www.integra-LS.com).

CONTACT: Integra LifeSciences Holdings Corporation John B. Henneman, III Executive Vice President Chief Administrative Officer (609) 936-2481 jhenneman@Integra-LS.com

Maria Platsis Director of Corporate Development and Investor Relations (609) 936-2333 mplatsis@Integra-LS.com